Monotherapy with Kutaj Parpati Is Effective in reducing Irritable Bowel Syndrome (IBS) Symptoms – A Randomized controlled, parallel group trial

[摘要] Background: Irritable bowel syndrome (IBS) is a disorder that causes diarrhoea, constipation, stomach discomfort andbloating. IBS symptoms are linked to Grahani roga. There are few trials with Kutaj parpati in IBS, but the findings areinconsistent. We tested the null hypothesis that there is no difference between the Kutaj parpati and placebo for improvementof symptoms of IBS.Materials and Methods: This is a randomized, single blind, placebo control trial. Sample size estimation was done to havepower of 80 % and 95% confidence interval. A total of 20 patients were enrolled in the trial who were diagnosed with irritablebowel syndrome according to the ROME 3 criteria. Group A received Kutaj parpati in a dose of 250 mg thrice a day whileGroup B received placebo. The patient rated the degree of abdominal discomfort, frequency of abdominal discomfort, severityof abdominal bloating, interference with daily activities, and satisfaction with bowel habits on a numeric rating scale (NRS)of 1-10 at three time points: one ,two and three months.Results: The demographic features of the individuals were similar. The most bothersome symptom was abdominal bloatingwith numeric rating scale (NRS) of 7.4± 0.942. There was improvement over the three months in other symptoms (Notstatistically significant). The statistical significance was achieved (p value 0.00015) with abdominal bloating after threemonths of therapy.Conclusion: Kutaj Parpati was beneficial in reducing abdominal bloating in IBS over a three month period; however it did notdemonstrate substantial improvement for other symptoms.

[学科分类] 医学（综合）

[关键词] Irritable bowel Syndrome;Kutaj Parpati;Monotherapy